Statement of deviation or variation for the quarter ended 31.12.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Samsrita Labs has filed its quarterly compliance report confirming there is no deviation or variation in the use of funds raised through a preferential issue on 18 July 2025, totaling ₹339.10 lakhs. Of the four stated purposes, working capital (₹52.10 lakhs) and repayment of unsecured loans to the promoter director (₹88.31 lakhs) were fully utilized. General corporate purposes (₹66.23 lakhs allocated) saw ₹20.83 lakhs deployed, while the ₹132.46 lakhs earmarked for investment in new projects or ventures remained undeployed during the quarter. The Audit Committee reviewed and confirmed compliance on 6 February 2026, and no monitoring agency was required given the issue size.
This is a routine SEBI compliance disclosure with no negative news — the company is on track with its stated use of funds. Shareholders may note that nearly half the raised amount is yet to be deployed, particularly the ₹132.46 lakhs meant for new investments, which could be a watchpoint for future updates on new projects.